Tanvex BioPharma USA, Inc. announced that it will raise $50 million in a round of funding on February 6, 2024. The transaction will include participation from returning investor, Tanvex BioPharma, Inc. The company will issue common stock in the transaction. The transaction has been approved at the board of directors of the company.